BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 3
• 4
• 5
• 6
• 7
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• BioMidwest

  Actuate Therapeutics Announces Poster Presentations at the 2023 AACR Annual Meeting

  Actuate Therapeutics, Inc. announced today three poster presentations from scientific collaborators at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-19, 2023, in Orlando, Florida.

  April 10, 2023

   · 

  1 min read
• Drug Development

  Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian CarcinomaPhase 1b study builds on highly consistent preclinical and Phase 1a data

  Nuvectis Pharma, Inc. today announced the initiation of the Phase 1b study for NXP800 in platinum-resistant, ARID1a-mutated ovarian carcinoma.

  April 10, 2023

   · 

  7 min read
• OBI Pharma Announces Poster Presentations at AACR 2023 Annual Meeting for OBI-999 combination synergy with checkpoint inhibitor as well as Globo H-targeted CAR T-cell immunotherapy

  OBI Pharma, Inc. announced preclinical data demonstrating significant synergistic effects of OBI-999 and pembrolizumab in four different cancer models, as well as the potent antitumor effect of a chimeric antigen receptor T-cell immunotherapy targeting Globo H.

  April 10, 2023

   · 

  3 min read
• Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research

  Bright Minds Biosciences Inc. today announced that Alex Vasilkevich, Bright Minds’ Scientific Officer, will present at the 20th International Meeting of the International Society for Serotonin Research (ISSR).

  April 10, 2023

   · 

  5 min read
• Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the National Kidney Foundation (NKF) 2023 Spring Clinical Meeting (SCM)

  Two scientific abstracts spanning clinical and health economic outcomes research will be presented at the 2023 NKF SCM, showcasing the breadth of Mallinckrodt’s commitment to HRS patients with rapid reduction in kidney function.

  April 10, 2023

   · 

  9 min read
• Business

  TScan Therapeutics Announces Appointment of Barbara Klencke, M.D., to its Board of Directors

  TScan Therapeutics, Inc. today announced the appointment of Barbara Klencke, M.D., to its Board of Directors, effective April 6, 2023.

  April 10, 2023

   · 

  9 min read
• Pharm Country

  Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at Prada Rong Zhai in Shanghai

  Tiziana Life Sciences Ltd. today announced that poster presentations on intranasal foralumab are being presented at the “Preserving the Brain” scientific conference and exhibit held at the Fondazione Prada in Rong Zhai in Shanghai.

  April 10, 2023

   · 

  2 min read
• Drug Development

  Evecxia Therapeutics Reports Favorable Data From a Phase 1 Single-Ascending Dose and Multiple-Ascending Dose Trial of Adjunctive EVX-101 in Healthy Volunteers Treated With a First-Line Antidepressant

  Evecxia Therapeutics, Inc. today announced favorable safety, tolerability, pharmacokinetic, and pharmacodynamic data from a double-blind, placebo-controlled Phase 1, a two-part single ascending dose (SAD) and multiple ascending dose (MAD) trial of EVX-101 in healthy volunteers treated with escitalopram.

  April 10, 2023

   · 

  5 min read
• Business

  Aviceda Therapeutics Announces Strategic Partnership with Queen’s University Belfast (QUB)

  Aviceda is partnering with world-renowned scientist Professor Christopher Scott and his teams at the Patrick G. Johnson Centre for Cancer Research at Queen’s University Belfast to spearhead development of the next generation of glyco-immune therapeutics.

  April 10, 2023

   · 

  5 min read
• BioMidwest

  Abeona Therapeutics Announces Multiple Abstracts Accepted from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

  Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the acceptance of three abstracts at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place from May 16-20, 2023 in Los Angeles, CA.

  April 10, 2023

   · 

  5 min read